WELCOMEFROM THE MEDICAL DIRECTORMARK KRASNA, M.D.The Cancer Institute at <strong>St</strong>. <strong>Joseph</strong> <strong>Medical</strong> <strong>Center</strong> is made up of fulltime,part-time and private physicians. This team collaborates to providetreatment for the entire spectrum of cancer—from solid organ tohematologic malignancies. The Cancer Institute <strong>Center</strong>s are designedaround specific organ sites to facilitate the best possible care forpatients. Our 33,400 square foot outpatient facility has further facilitatedimprovements in person-centered cancer care delivery, allowing our uniquemultidisciplinary approach to provide all cancer care under one roof.The Cancer Institute truly embodies the concept of patient-centeredmultidisciplinary care. The facility, scheduling and administrativestructure allow patients to be seen at one visit by all the necessaryspecialties pertaining to each individual case, including medical,radiation and surgical oncology. In addition, there is easy access to otherspecialists, such as pulmonologists, gastroenterologists, radiologists,dieticians, genetic counselors, physical therapists and social workerswithout the patient having to move to a different facility or location.Disease-specific multidisciplinary care clinics, prospective weeklydisease-specific conferences and clinical research trials are a regularpart of the comprehensive cancer care provided.The Cancer Institute houses all cancer outpatient services, including:outpatient infusion areas, a dedicated cancer pharmacy and researchpharmacy, dedicated PET/CT unit, outpatient radiation oncology, cancerresearch offices, community outreach, nurse navigators/coordinators,social services, pastoral care and the Tumor Registry.The Comprehensive Breast Oncology <strong>Center</strong>, which opened in October2007, has now exceeded its capacity, resulting in a 4300 square footexpansion for the new Women’s Oncology <strong>Center</strong>. This unit houses theoutpatient evaluation and biopsy programs as well as breast imagingservices, including mammography, ultrasound, dexa scan and X-ray.Likewise, our expanding Gynecologic Oncology program is moving intothis enlarged space, giving our female patients the sense of belongingto one unique Women’s Oncology <strong>Center</strong>. Our Serpick Infusion <strong>Center</strong>has grown beyond all expectations with the resulting need for expansionin this area as well. Additional chemotherapy infusion chairs, designedand patented by Dr. Krasna for the Cancer Institute, as well as additionalmedical oncology and nursing staff will be added by June 2010.This past year saw the beginning of year three of our NationalCommunity Cancer <strong>Center</strong> Program (NCCCP), the only NCI communitycancer program in Maryland. This program has been granted anexpansion for a fourth year due to its success as well as opportunitiesfor additional grant funding from the National Cancer Institute (NCI). Thisyear also marks the beginning of our participation in the National CancerInstitute’s Cancer Genome Project (TCGA). The Cancer Institute is the firstcommunity cancer center in the country to participate in tissue collection,and its team is working with the NCI to define best practices in cancertissue collection, storage and research, to understand the root causesof cancer in the future, and to allow better opportunities to developpersonalized cancer treatments.
This year we also opened our new stereotactic radiosurgery unit in theRadiation Oncology <strong>Center</strong>. The most exciting alternative to surgery fortumors—radiosurgery—is now available to <strong>St</strong>. <strong>Joseph</strong> Cancer Institutepatients with the installation of a hybrid Trilogy linear accelerator witha Clinac IX stereotactic radiosurgery arm. Radiosurgery allows us toperform local treatment of tumors and is similar to surgery without a knife,by delivering a high radiation dose in a very precise volume. Multi-leafcollimators, which are thin metal sliding mechanisms, shape the radiationbeam, so that it can be altered to avoid normal, healthy tissue. Dr. JasonCitron, medical director of the Radiation Oncology <strong>Center</strong>, Dr. Neal Naff,chief of Neurosurgery, Dr. Ziv Gamliel, chief of Thoracic Surgery, andDr. Justin Tortolani of the Orthopedic Institute have participated in treatinginoperable tumors of brain, lung and bone cancers since its installationthis past April. Although the main application for radiosurgery has beenbrain metastases, meningiomas and other benign brain tumors, cerebralarteriovenous malformations and pituitary adenomas, we will expand itsuses in the future and investigate treating inoperable lung cancer, softtissue cancers and liver mestatases.Finally, our Cancer Committee, ably led by Dr. Maen Farha, hasdeveloped admirable quality improvement goals each year which havebeen instrumental in improving patient care. Likewise, they have approveda draft “conditions of participation” at the suggestion of the NCI to betterdefine and recognize appropriate Cancer Institute participation on thepart of physicians across the <strong>Medical</strong> <strong>Center</strong>.The Cancer Institute at <strong>St</strong>. <strong>Joseph</strong> <strong>Medical</strong> <strong>Center</strong>.CENTER HEADSBreast Oncology <strong>Center</strong> Director s Michael Schultz, M.D.Colorectal Oncology <strong>Center</strong> Director s Howard Berg, M.D.Genitourinary Oncology <strong>Center</strong> Director s Marc Siegelbaum, M.D.Gynecologic Oncology <strong>Center</strong> Director s Neil Rosenshein, M.D.Hepatobiliary Oncology <strong>Center</strong> Director s Mark Fraiman, M.D.<strong>Medical</strong> Oncology s Rima Couzi, M.D.s Richard Schraeder, M.D.Radiation Oncology Director s Jason Citron, M.D.Thoracic Oncology <strong>Center</strong> Director s Ziv Gamliel, M.D.Neuro-Oncology <strong>Center</strong> s Neal Naff, M.D.